-
ChemoCentryx's Drug Gets U.S. FDA Nod For Treating Rare Autoimmune Disease Opens in a new window)
The drug, avacopan, which will be available under brand name Tavneos in the next few weeks, will have a wholesale price of between $150,000 and $200,000 per patient per year. -
Drug Price Negotiation Doesn’t Mean the Government Will Restrict Access to Medicines Opens in a new window)
In fact, the proposed drug price negotiation program does not authorize the federal government to decide which medications people on Medicare can and cannot get and does not establish or require a particular prescription drug formulary.Comments
-
Biosimilars Competition Helps Patients More Than Generic Competition Opens in a new window)
A notion in the policy community is that competition between biologics and their biosimilars does not save patients and taxpayers as much as well-functioning generic competition.Comments
-
‘Naively Ambitious’: How COVAX Failed on its Promise to Vaccinate the World Opens in a new window)
Conceived at the start of the pandemic, COVAX had lofty goals, promising fair and equitable access to Covid-19 vaccines for every country worldwide, and giving them for free to the poorest.Comments
-
A Federal Drug Purchasing Program Could Save Billions Opens in a new window)
Medicare and a host of other federal agencies are prohibited by law from accessing this kind of purchasing power.Comments
-
Vancouver Votes to Support Application That Would Create Safe Drug 'Compassion Clubs' Opens in a new window)
Vancouver City Council has voted to support a federal application that would allow a "compassion club" model and provide tested drugs in the city.Comments
-
Africans Welcome New Malaria Vaccine. But Is It a ‘Game Changer'? Opens in a new window)
When babies are born in western Kenya, where malaria is rife, many mothers are sent home from the hospital with one all-important baby gift: a bed net treated with insecticide.Comments
-
B.C. to fund 'game changer' cystic fibrosis drug Trikafta Opens in a new window)
The B.C. government has also announced a new provincially co-ordinated model of care for cystic fibrosis patients.Comments
-
Buyers Clamor for Merck's COVID-19 Antiviral Molnupiravir, but Pricing is Already Controversial Opens in a new window)
Less than a week after Merck and Ridgeback released extraordinary data on the effectiveness of experimental COVID-19 drug molnupiravir, the rush is on to lock up supplies.Comments
-
Winnipeg Family Urges Province to Cover the Cost of New Cystic Fibrosis Drug Opens in a new window)
'We might need to make a move if Manitoba can't make a decision quickly,' says mom of boy with cystic fibrosis.Comments
-
‘Postcode Lottery’: Where You Live Determines Your Chances of Surviving Cancer, Inquiry Hears Opens in a new window)
Cancer outcomes in Australia are among the best in the world, except for those in rural and remote areas.Comments
-
NICE Recommends First New Sickle Cell Disease Treatment in 20 Years Opens in a new window)
NICE has announced on Tuesday that for the first time in 20 years, a new treatment will be made available on the NHS for sickle cell disease.Comments
-
Rapid COVID-19 Tests Increasingly Scarce, Pricey as Demand from Employers Jumps Opens in a new window)
Nearly a dozen state governments said they are grappling with shortages of rapid tests, which provide on-the-spot results within minutes and are crucial for COVID-19 surveillance programs.Comments
-
‘Pharma Bro’ Review: Behind the Smirk Opens in a new window)
This documentary grasps at straws trying to prove that the former pharmaceutical executive Martin Shkreli might not be as loathsome as his reputation suggests.Comments
-
Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What it Costs to Make Opens in a new window)
The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.Comments
Comments